Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Martinelli

Showing results (81-90 of 658) with videos related to

Pageof 66
Sort By:
Leukemia Research|August 1, 2009
mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL proteinManuela Mancini, Valentina Corradi, Sara Petta, et al.
Journal of Cellular Biochemistry|November 13, 2014
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemiaElisa Leo, Manuela Mancini, Fausto Castagnetti, et al.
Blood Transfusion = Trasfusione Del Sangue|November 2, 2012
Successful mobilisation of peripheral blood stem cells in children using plerixafor: a case report and review of the literatureAngelo Gardellini, Aleksandra Babic, Federica Gigli, et al.
Minerva Medica|September 21, 2020
Enasidenib and ivosidenib in AMLMaria Paola Martelli, Giovanni Martino, Valeria Cardinali, et al.
Haematologica|December 8, 2011
Chronic myeloid leukemia: the basis of treatment for tomorrowAngelo M Carella, John M Goldman, Giovanni Martinelli, et al.
FEBS Letters|November 12, 2009
c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migrationAnna Baruzzi, Ilaria Iacobucci, Simona Soverini, et al.
Haematologica|April 12, 2003
Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual diseaseGiuseppe Visani, Pier Paolo Piccaluga, Giovanni Martinelli, et al.
Expert Opinion on Biological Therapy|October 6, 2007
Imatinib mesylate in the treatment of hematologic malignanciesPier Paolo Piccaluga, Michela Rondoni, Stefania Paolini, et al.
Panminerva Medica|September 21, 2020
Monoclonal antibodies in multiple myelomaFederico Vozella, Francesca Fazio, Gianfranco Lapietra, et al.
Minerva Medica|September 21, 2020
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical useNurul A Abdul-Hamil, Gee C Wong, Chandramouli Nagarajan, et al.
Pageof 66

Showing results (81-90 of 658) with videos related to

Sort By:
Pageof 66
Leukemia Research|August 1, 2009
mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL proteinManuela Mancini, Valentina Corradi, Sara Petta, et al.
Journal of Cellular Biochemistry|November 13, 2014
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemiaElisa Leo, Manuela Mancini, Fausto Castagnetti, et al.
Blood Transfusion = Trasfusione Del Sangue|November 2, 2012
Successful mobilisation of peripheral blood stem cells in children using plerixafor: a case report and review of the literatureAngelo Gardellini, Aleksandra Babic, Federica Gigli, et al.
Minerva Medica|September 21, 2020
Enasidenib and ivosidenib in AMLMaria Paola Martelli, Giovanni Martino, Valeria Cardinali, et al.
Haematologica|December 8, 2011
Chronic myeloid leukemia: the basis of treatment for tomorrowAngelo M Carella, John M Goldman, Giovanni Martinelli, et al.
FEBS Letters|November 12, 2009
c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migrationAnna Baruzzi, Ilaria Iacobucci, Simona Soverini, et al.
Haematologica|April 12, 2003
Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual diseaseGiuseppe Visani, Pier Paolo Piccaluga, Giovanni Martinelli, et al.
Expert Opinion on Biological Therapy|October 6, 2007
Imatinib mesylate in the treatment of hematologic malignanciesPier Paolo Piccaluga, Michela Rondoni, Stefania Paolini, et al.
Panminerva Medica|September 21, 2020
Monoclonal antibodies in multiple myelomaFederico Vozella, Francesca Fazio, Gianfranco Lapietra, et al.
Minerva Medica|September 21, 2020
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical useNurul A Abdul-Hamil, Gee C Wong, Chandramouli Nagarajan, et al.
Pageof 66